ABSTRACT
disorder has distinct gross and microscopic pathologies. PD is marked by the loss of dopamine neurons in the substantia nigra (SN). 3 MSA is characterized neuropathologically by glial and neuronal cytoplasmic inclusions in many basal ganglia and cerebellar related structures, 4 whereas PSP has neuronal loss, gliosis, and neurofibrillary tangles in both the basal ganglia and cerebellum that may extend to limbic areas. 5, 6 Two MR imaging modalities, diffusion tensor imaging and the apparent transverse relaxation rate (R2*), have been studied intensively in recent decades with the goal of detecting the distinct pathologic patterns in PD, MSA, and PSP and differentiating them from each other. [7] [8] [9] [10] [11] [12] [13] DTI has been suggested to reflect the disruption of microstructural integrity (eg, cell death and associated myelin changes), whereas R2* has been used to estimate iron accumulation in brain tissue. 14, 15 There has been little effort, however, to directly compare DTI and R2* in the differential diagnosis of PD and atypical parkinsonism, and in testing whether they can provide complementary information regarding pathology and/or discriminability of those diseases. 10, 14 In the current study, we compared the pattern of DTI and R2* changes among the different parkinsonian diseases and a control group in multiple ROIs that included striatal-, midbrain-, limbic-, and cerebellar-related structures. The performance of DTI, R2*, and their combination to discriminate controls from patient groups and patient groups from each other also was assessed by using an Elastic-Net machine learning approach with a nested 10-fold cross-validation. 35 with PD, and 36 healthy controls) were included in this study from an ongoing longitudinal case-control cohort established in 2012. Patients were recruited from a tertiary movement disorders clinic, and controls were recruited from the spouse population of the clinic or the local community. All patients were free of major neurologic/medical issues other than PD, MSA-P, or PSP, and all controls were free of any known neurologic/psychiatric diagnoses. Patient diagnoses were initially established according to published criteria [16] [17] [18] by a movement disorder specialist and updated (August 2016) before the analysis of the current data according to the most recent clinical assessment and postmortem pathology if available (5 PD and 3 PSP cases were confirmed by postmortem pathology results). Two subjects (1 with PD and 1 with PSP) were excluded from later analyses due to severe motion artifacts. Disease duration was defined as the number of years between the date when a parkinsonian syndrome was first diagnosed by a medical professional and the study visit date. All participants were administered the Movement Disorder Society Unified Parkinson's Disease Rating Scale part III (UPDRS-III) for motor function assessment and the Montreal Cognitive Assessment (MoCA) for global cognitive function. 19 
MATERIALS AND METHODS

Subjects
UPDRS-III and
MoCA scores and MR imaging scans were collected for patients in an "on" state. The study was approved by the institutional review board at the Pennsylvania State University-Milton S. Hershey Medical Center. All subjects provided written informed consent.
MR Imaging Data Acquisition
Brain MRIs were obtained from all participants by using a 3T MR imaging system (Magnetom Trio; Siemens, Erlangen, Germany) with an 8-channel phased array head coil. The MR imaging examination included multi-gradient-echo (for R2*) and diffusion tensor imaging sequences, along with high-resolution T1-weighted and T2-weighted images for segmentation. Detailed imaging parameters are described in the On-line Appendix.
DTI and R2* Maps
Diffusion tensor images were processed using DTIPrep (Neuro Image Research and Analysis Laboratory, University of North Carolina, Chapel Hill, North Carolina). In DTIPrep, a thorough quality control for diffusion-weighted images was performed by intersection and intervolume correlation analysis, eddy currents, and motion artifact correction. Fractional anisotropy (FA) and mean diffusivity (MD) maps were then estimated for subsequent analysis. For R2*, an affine registration was used to align 6 magnitude images to an averaged mean magnitude image for potential head motion correction in multi-gradient-echo images. The R2* maps then were generated by using a voxelwise nonlinear LevenbergMarquardt algorithm to fit a monoexponential function (s ϭ s 0 e ϪTE ϫ R2* ) by using an in-house Matlab (MathWorks, Natick, Massachusetts) tool.
ROI Segmentation
The segmentation of ROIs was performed by using the Advanced Normalization Tools software package (ANTs; http://stnava. github.io/ANTs/) 20 and an atlas-based segmentation pipeline implemented in AutoSeg (http://www.nitrc.org/projects/autoseg/), 21 along with an in-house atlas. An unbiased, age-appropriate template was generated from T1-weighted images from all controls with ANTs. 22 The following 13 ROIs, including striatal and related struc- Appendix for details regarding the segmentation process). On-line Fig 3 illustrates the segmentation quality for small structures (SN, RN, and superior cerebellar peduncle). B0 images for DTI and mean magnitude images for R2* then were coregistered to individual T2-weighted images using ANTs. The resulting transformations were then applied to FA, MD, and R2* maps by using a B-spline interpolation to bring FA, MD, and R2* images into the same space as the segmented ROIs, where the mean values of FA, MD, and R2* for each ROI were calculated for subsequent analyses.
Statistical Analysis and Modeling
The difference in sex frequency among groups was evaluated by using the 2 test. Age and disease duration were compared by using 1-way analysis of variance. MoCA and UPDRS-III scores among groups were assessed by using 1-way analyses of covariance with adjustments for age and sex. Each MR imaging measurement in patients with PD, MSA-P, and PSP was compared with that of controls by using univariate ANCOVAs with age and sex as covariates for each of the 13 ROIs. For MR imaging measurements, the Bonferroni method was used to correct for multiple comparisons, with a resulting P value Յ .0038 (0.05/13 independent tests) considered significant.
One major challenge for multimodal MR imaging studies is the high dimensionality of potential predictors generated from different MR imaging measurements and brain structures, which can result in overfitting and collinearity among variables, causing traditional analyses to fail. In this study, we used an Elastic Net regularized logistic regression approach with a nested 10-fold cross-validation scheme to unravel the highdimensional problem. Two hyperparameters need to be defined in Elastic-Net regularized regression. In our study, ␣ was fixed to 0.2 empirically and was selected by an inner layer 10-fold cross-validation that was independent of the outer layer 10-fold cross-validation used for performance evaluation. This nested cross-validation setting was implemented to alleviate potential overfitting. 24 Regularized logistic models were built from all ROI measurements including R2*, DTI (including both FA and MD), and the combined measures (R2*, FA, and MD) for discriminating the following: 1) controls from those with PD/MSA-P/PSP, 2) those with PD from those with MSA-P/PSP, 3) controls from those with PD, 4) those with PD from those with MSA-P, 5) those with PD from those with PSP, and 6) those with MSA-P from those with PSP. Receiver operating characteristic (ROC) curves were generated by using outer layer 10-fold cross-validation models for each MR imaging technique and their combination. A bootstrap approach was used to test the differences among ROC curves. 25 ROC curve comparisons were performed between the combined marker and DTI because DTI was better or equal to R2* in all 6 scenarios mentioned above. Sensitivity, specificity, positive predictive value, and negative predictive value were generated by using the Youden method.
Statistical analyses were performed by using the open-source statistical software package R (Version 3.0.3; http://www.rproject.org). Elastic-Net regularized logistic regression was conducted by using the R package glmnet (http://web.stanford.edu/ ϳhastie/glmnet/glmnet_alpha.html), 26 whereas the ROC curve analyses were performed by using the R package pROC (https://cran.r-project. org/web/packages/pROC/index.html).
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RESULTS
Demographic Data
Demographic characteristics for subjects are shown in Table 1 . No significant overall differences in sex distribution or age were detected among the control, PD, PSP, and MSA-P groups. Post hoc pair-wise analysis showed trending differences between MSA-P and PSP in both sex (P ϭ .072) and age (P ϭ .065). Thus, both age and sex were entered as covariates for group comparisons. Logistic regression on age and sex showed no comparable discriminability among PD, MSA-P, and PSP (area under the curve Ͻ 0.66). Although patients had significantly lower MoCA and higher UPDRS-III scores compared with controls, there were no significant differences among the patient groups on the clinical measures (disease duration, MoCA, or UPDRS-III).
DTI and R2* Comparison between Parkinsonian Disease and Control Groups
Compared with controls, patients with PD showed changes in the posterior SN and RN in both DTI and R2*, though only the R2* value in the RN survived correction for multicomparisons. Patients with both MSA and PSP showed more widespread changes (after correction for multicomparisons) involving structures both within and outside the midbrain. The pattern of changes, however, was different between the 2 groups. Namely, patients with MSA-P showed increased MD values in the PUT, globus pallidus, cerebellum, and middle cerebellar peduncle, a decreased FA value in the STN, and increased R2* values in the STN and middle cerebellar peduncle. Patients with PSP, however, showed increased MD and R2* values in the posterior substantia nigra but no changes in the STN or any other basal ganglia structures. Patients with PSP had significantly increased MD values in the dentate nucleus, cerebellum, and superior cerebellar peduncle, but not in the middle cerebellar peduncle (Table 2 and  On-line Table) .
Discriminative Analysis
We compared the discriminative ability of DTI and R2* measures and their combination under 6 different scenarios by using ElasticNet regularized logistic regression and ROC curves (Table 3 and Online Fig 2) . The combined models (DTIϩR2*) were better than DTI or R2* alone (Ps Ͻ .05) in discriminating controls from those with PD/MSA-P/PSP, controls from those with PD, those with PD from those with MSA-P/PSP, and those with PD from those with MSA-P. When we considered the separation of controls from subjects with PD, the combined model was improved dramatically compared with either measure alone (from area under the curve ϭ 0.82 to area under the curve ϭ 0.91, P ϭ .001).
The DTI model, however, showed strong discriminability when differentiating PD from PSP (area under the curve ϭ 0.97) or MSA-P from PSP (area under the curve ϭ 0.96), and adding R2* did not significantly improve the performance of the model. Nevertheless, R2* alone showed decent discriminative ability b Group difference in sex was compared among all 4 groups using the 2 test. c Group differences in age and disease duration were compared using 1-way ANOVA. d Group differences in MoCA and UPDRS-III were compared among all 4 groups using ANCOVA with adjustments for age and sex. e Group differences in MoCA and UPDRS-III were compared among the 3 patient groups, using ANCOVA with adjustments for age and sex.
when differentiating PD from PSP (area under the curve ϭ 0.87) and MSA-P from PSP (area under the curve ϭ 0.89).
DISCUSSION
First, we confirmed that DTI and R2* differentiate parkinsonian syndromes and controls. In addition, our studies demonstrated that DTI and R2* can capture the distinct pathologic patterns of the different parkinsonian syndromes and may provide complementary information about each disease. Individually, DTI showed better discriminability among the disease groups, whereas R2 added significant value in separating controls from those with parkinsonian syndromes and those with PD from those with MSA-P/PSP or MSA-P.
DTI and R2* Changes in PD
The pathologic hallmark of PD is neuronal loss in the SN pars compacta. Our study may capture this pathology by demonstrating decreased FA and increased R2* in the posterior SN. 28, 29 The inclusion of additional ROIs in our study, however, requires a rather conservative Bonferroni correction; thus, the detected difference did not reach statistical significance. Future studies are needed to confirm these findings in light of a recent meta-analysis suggesting that nigral FA changes in patients with PD vary widely. 30 In the current study, patients with PD also demonstrated increased R2* values in the RN. This result is consistent with the notion that the RN may be involved in the primary cerebellar motor pathway, which has been shown to be affected in PD.
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DTI and R2* Changes in MSA-P
We also found significantly increased MD values in the PUT, globus pallidus, cerebellum, and middle cerebellar peduncle of patients with MSA-P, consistent with previous neuroimaging results. 7 Note:-Sens indicates sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the curve; C, controls. a ROC curves were compared between the models, including all MRI measurements and that with DTI measurements only. b Models for DTI measurements were generated by including both FA and MD features.
Patients with MSA-P consistently demonstrated increased R2* values in the PUT. [10] [11] [12] The current study, however, failed to detect R2* changes in the PUT of these patients. linear fitting after log-transformation of the original signal, whereas the current study used nonlinear curve-fitting to a monoexponential function similar to that in Barbagallo et al. 12 Most interesting, we detected a decreased FA value in the STN of patients with MSA-P, along with an increased R2* value, which has not been reported by any previous MR imaging studies, to our knowledge. It is unclear whether the lack of significant STN findings arises from a lack of focus on this structure or whether no differences were found. The neuronal/glial cytoplasmic inclusions that typically are found in basal ganglia regions are less common in the STN of patients with MSA. 4 One pathology study, however, noted increased microglia in the STN of patients with MSA-P, 36 which may reflect a reactive or compensatory process instead of the primary pathology. Thus, the STN changes we detected may reflect these reactive or compensatory changes, though future studies focused on the STN are warranted to verify this.
DTI and R2* Changes in PSP
Consistent with previous studies, we found significant DTI (MD) changes in midbrain (posterior SN and cerebellar [cerebellum and superior cerebellar peduncle]) structures of patients with PSP, with the most robust change seen in the superior cerebellar peduncle. 7, 8, 35, 39 Whereas most studies reported increased MD values in the PUT of patients with PSP, 35 ,39,40 we did not detect MD changes in the PUT or other basal ganglia structures (CN and globus pallidus) in the current study. Consistent with our findings, Tsukamoto et al 34 reported no MD changes in the PUT of patients with PSP. Additional studies are needed to clarify the discrepancies.
In the past, both pathologic and neuroimaging studies with free-water imaging suggested changes in the STN of patients with PSP. 6, 13 Pathologic studies also reported both neuronal and oligodendroglia loss in the STN of patients with PSP. Using traditional DTI measures (FA and MD), the current study did not detect significant changes in the STN of patients with PSP. It is possible that the mixed microscopic pathology may have complex or opposing effects on these traditional DTI measurements at the macroscopic level. Change in the STN of patients with PSP by means of the free-water measure derived from a bi-tensor model 13 suggests that free-water may be a more sensitive marker for PSP-related pathology in the STN. Future studies are needed to further confirm the links between PSP-related pathology and different MR imaging contrasts.
In the current study, we also detected an increased MD value in the dentate nucleus of patients with PSP. Although this finding is new, it is in line with pathologic results of neuronal loss in the dentate nucleus of patients with PSP. 6 In addition, patients with PSP demonstrated significantly increased MD values in the hippocampus and a trending change in the amygdala. These results are consistent with previous volumetric studies suggesting pathologic involvement of the hippocampus in PSP 5, 41 and early cognitive issues that often are detected in patients with PSP clinically. These findings are inconsistent, however, with previous pathologic studies indicating that the hippocampus and amygdala are spared from pathology in patients with PSP. 42 A growing literature supports the heterogeneity of PSP and mixed pathologic findings across different tauopathies 39, 43 ; thus, the value of using differential imaging patterns to subtype the patient with PSP will be evaluated in the future. Previous studies on R2* in the PUT, CN, and globus pallidus in patients with PSP have been controversial because some studies showed significantly increased R2* values in these structures, 11, 44 whereas others did not. 10 The current results are consistent with no R2* changes in the PUT, CN, and globus pallidus. Patients with PSP, however, had significantly increased R2* values in the SN and RN. This finding is consistent with previous PSP pathologic studies indicating that pathology-related neuronal and oligodendroglia loss is involved in both the SN and RN.
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Discriminative Analysis
Many promising MR imaging markers have been suggested to differentiate patients with PD from those with atypical parkinsonism. 8, 9, 13, 45, 46 Systematic comparison and validation of those markers in the same subjects are needed before translating these findings into a clinical setting. The current study is the first to systematically compare DTI, R2*, and their combination by using Elastic-Net regularized logistic regression. When we compared DTI and R2* measures under 6 clinically relevant scenarios, our results suggested the following: 1) that DTI measures overall are better or comparable with R2* values in differentiating parkinsonisms, and 2) that R2* provides complementary information in most scenarios except when differentiating PD from PSP or MSA-P from PSP.
Limitations
The current study has some limitations. First, among 70 patients with parkinsonism, only 8 cases were confirmed by postmortem pathology. Despite updating the clinical diagnosis by integrating more longitudinal clinical information right before conducting the current analysis, diagnosis error inevitably exists and might bias the results. Additionally, we included controls with positive UPDRS-III scores as high as 14. It is possible that controls with high UPDRS-III scores have a preclinical parkinsonian syndrome. Nonetheless, a recent study has demonstrated that parkinsonian signs are common in older adults, even without a clinical diagnosis of disease. 47 Second, this study is case-control in nature and does not simulate clinical practice, which would include other diseases potentially confused with PD such as essential tremor, corticobasal degeneration, dementia with Lewy bodies, and psychogenic disorders. In addition, we did not separate PSP subtypes. 43 Re-analyzing the data to include only patients with PSP
Richardson subtype (n ϭ 13) did not change the results demonstrably from those including the entire PSP cohort. Finally, in the current study, all data were collected while patients were on antiparkinsonian medications, and the MR imaging measures may be affected by the drugs. Further prospective studies that mimic clinical practice are warranted to further test the potential of these markers in clinical practice. Technically, recent advances in MR imaging markers for PD and atypical parkinsonism have suggested that 2 new measures (free-water and quantitative susceptibility) may be useful for discriminating patient groups and are derived from the same MR imaging data (DTI and R2*, respectively). Quantitative susceptibility has been suggested to improve the R2* signal by reducing potential confounders of the iron measurement, 48 whereas free-water may provide additional information above traditional FA or MD values. 49 The current study did not include these new measures, and future work validating and comparing them is warranted. Finally, this study did not compare our models with conventional MR imaging clues used by radiologists in these disorders, such as the "hummingbird" and "hot cross bun" signs, midbrain atrophy, and putaminal T2-weighted hypointensity. [50] [51] [52] Notably, Reiter et al, 51 with visual rating of dorsolateral nigral hyperintensity in susceptibility-weighted images, showed promising discriminability in differentiating those with parkinsonian syndromes from controls. It will be important to discern the additional value a quantitative MR imaging marker derived from combining DTI and R2* provides compared with the best medical knowledge. In this study, we adopted an Elastic-Net regularized regression as the multivariate classification method. Even though we used a nested 10-fold cross-validation for model selection and performance evaluation, the models still may be overly optimistic due to the small sample size.
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CONCLUSIONS
Our findings are consistent with those in previous neuroimaging and postmortem pathologic studies reporting significant involvement of striatal-, midbrain-, and cerebellar-related structures in PD and atypical parkinsonism. 4, 6, 8, 10, 12, 14, 15, 29, 34, 35, 39 The exact location and MR imaging measures in striatal and midbrainrelated structures between previous studies and the current study, however, vary. 34, 35, 39 This study demonstrated that DTI and R2* reflect different-yet-complementary information that can be used for discriminating controls and patients with PD, MSA, and PSP. Further refinement of this approach, including the use of novel measures that assess other aspects of disease pathology and the extension to whole-brain feature space, could lead to an optimized tool that can diagnose and differentiate PD from atypical parkinsonism. We envision applying this approach to a large prospective cohort, including a more diverse patient population (PD, MSA, PSP, essential tremor, corticobasal degeneration, and dementia with Lewy bodies), that simulates a real clinical setting to further test its utility in clinical practice.
